Skip to main content

This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Home
NICE

Get in touch

Menu

Prescribing Information

NICE recommendation

TZIELD can be used, within its marketing authorisation, as an option for delaying the onset of Stage 3 Type 1 diabetes (T1D) in people 8 years and over with Stage 2 T1D1

TZIELD is only recommended if the company provides it according to the commercial arrangement1

What does this mean?

Within the recommended population, TZIELD provides benefit and value for money1

Availability

If TZIELD is considered the most suitable treatment option, it must be funded by the NHS, according to the NICE recommendation within:1

  • 90 days of final guidance publication in England
  • 60 days of final draft guidance in Wales

NICE guidance is typically adopted in Northern Ireland, subject to local health system review and formal endorsement by the Department of Health and Social Care (HSC)2

To find out more about setting up a TZIELD infusion service, visit our Payer Portal

Testing and screening context

Identifying patients with Stage 2 T1D requires both autoantibody (AAb) testing (≥2 islet AAbs) and evidence of dysglycaemia.3 Currently, Stage 2 patients are identified through research studies (such as ELSA & T1DRA), clinical assessment, first-degree relative (FDR), or patient request.1

The NICE guidance acknowledges that new NHS testing pathways will need to be established to support TZIELD implementation.1 Importantly, the relevant real-world costs of testing eligible FDRs have already been accounted for within the confidential net price agreed for TZIELD.

NICE's economic model reflects the expected FDR testing activity required to identify people eligible for treatment, based on up to 43 FDRs tested for every 1 person treated with TZIELD.1 This means FDR testing should not be viewed as a separate, unfunded activity sitting outside the NICE recommendation – it is part of the funded implementation pathway, and NHS funding is available to cover both TZIELD treatment and the associated FDR testing costs.

The availability of TZIELD is expected to incrementally increase the number of people who come forward for NHS-funded AAb testing, but the most likely cost-effectiveness estimates remain within the range NICE considers an acceptable use of NHS resources.

First-degree relatives of people with type 1 diabetes represent the primary population for testing, as they have significantly higher risk, compared to the general population.4 

Healthcare professionals should feel able to discuss and request AAb testing for eligible FDRs and their families, in line with the testing activity already recognised and funded within the NICE recommendation.

Find out more about the risk factors for autoimmune T1D here.

To read the full NICE guidance, click here.    
By following the link above, you will be directed to the official NICE guidance for TZIELD, which Sanofi has no control over. Sanofi accepts no responsibility for the content or availability of the website.

INDICATION: TZIELD is indicated to delay the onset of Stage 3 T1D in adult and paediatric patients 8 years of age and older with 
Stage 2 T1D.5

AAB, autoantibody; ELSA, Early Surveillance for Autoimmune Diabetes; FDR, first-degree relative; NHS, National Health Service; NICE, National Institute for Health and Care Excellence; T1D, type 1 diabetes; T1DRA, Type 1 Diabetes Risk in Adults.

  1. NICE. Final Guidance. Teplizumab for delaying the onset of Stage 3 type 1 diabetes in people 8 years and over with stage 2 type 1 diabetes. Available at: https://www.nice.org.uk/guidance/ta1176. Accessed August 2026.
  2. Department of Health. National Institute for Health and Care Excellence (NICE) Technology Appraisals – Process for Endorsement, Implementation, Monitoring and Assurance in Northern Ireland. Available at: https://www.health-ni.gov.uk/publications/circular-hsc-sqsd-12-22-nice-technology-appraisals-process-endorsement-implementation-monitoring-and-assurance-northern-Ireland. Accessed August 2026.
  3. Sims EK, et al. Diabetes. 2022: 71: 610–623.
  4. Besser EJ, et al. Pediatr Diabetes. 2022; 23: 1175–1187.
  5. TZIELD® (teplizumab) UK Summary of Product Characteristics.

MAT-XU-2601920 (V1.0) | September 2026